openPR Logo
Press release

Dilated Cardiomyopathy Market Size, Analysis, and Forecast Report 2017-2027

02-05-2018 01:25 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Future Market Insights

Dilated Cardiomyopathy Market Size, Analysis, and Forecast

Dilated cardiomyopathy is condition caused due to enlargement of left ventricle in the heart. In this state left ventricle gets enlarged, and the heart walls become thinner to pump blood from heart to other body parts of the body. Dilated cardiomyopathy can be developed at any age however it is more common in the people age between 20 to 60 years. In some cases, right ventricle also might be affected due to myopathy. Dilated cardiomyopathy is often caused by genetic mutations and non-genetic conditions like exposure to toxins, autoimmune diseases, heart valve abnormalities and diabetes disease conditions. However, there was no drug approved by FDA to treat dilated cardiomyopathy conditions. Companies are actively working on to develop molecules to treat dilated cardiomyopathy conditions. Array BioPharma carrying out Phase 2 clinical trial for ARRY-797 that inhibits p38 mitogen-activated kinase inhibitor to treat dilated cardiomyopathy. In December 2015, U.S. FDA gave Orphan drug status to the Vasomera (PB1046) molecule developed by PhaseBio Pharmaceuticals that is used treat X-linked dilated cardiomyopathy conditions. Vericel Corporation working on innovative concept to treat dilated cardiomyopathy conditions. Company has developed Ixmyelocel-T, multicellular therapy to treat dilated cardiomyopathy.

Dilated Cardiomyopathy Market: Drivers and Restraints

Globally increase in incidences of congestive heart failure conditions which is leading cause of dilated cardiomyopathy conditions. According to American Heart Association, around 5.3 million Americans have congestive heart failure within an incidence of 660,000 cases diagnosed yearly this signifies potential of the market. The major restraints for the market lack of proper drugs, increase in usage of defibrillators and pacemakers are effecting growth of this market.

Request Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2830

Dilated Cardiomyopathy Market: Segmentation

The global Dilated Cardiomyopathy Market is classified on the basis of drug class, distribution channel and geography.

Based on drug class, the dilated cardiomyopathy market is segmented into the following:

Angiotensin-converting enzyme (ACE) inhibitors

Angiotensin II receptor blockers

Beta blockers

Diuretics

Blood thinning medications

Cardiac glycosides

Based on distribution channel, the dilated cardiomyopathy market is segmented into the following:

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Mail order Pharmacies

Visit For TOC@ https://www.futuremarketinsights.com/toc/rep-gb-2830

Dilated Cardiomyopathy Market: Overview

Normally to treat dilated cardiomyopathy conditions, physicians use the drugs that can treat for congestive heart failure conditions this is due to lack of drugs for dilated cardiomyopathy conditions. Angiotensin receptor blockers occupy the major market share followed by beta blockers by beta blockers. In case of distribution channel, retail pharmacies hold the major market share followed by hospital pharmacies due to easy availability of drugs.

Dilated Cardiomyopathy Market: Regional Overview

Dilated Cardiomyopathy Market is classified into seven regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America occupies the significant market share in dilated cardiomyopathy market. Due to high incidence rates of congestive heart failures in the region. Next to North America, Europe holds the second leading market share for dilated cardiomyopathy conditions. According to European Federation of Pharmaceutical Industries and Associations, over 6000,000 are admitted to hospital, and 55,000 deaths are caused due to the congestive heart failure conditions in Europe. However, APEJ market is expected to grow over the forecast due to increase in awareness and increasing demand for generic drugs are responsible for growth of the market over the forecast period.

Dilated Cardiomyopathy Market: Players

Some of the players in the dilated cardiomyopathy Pfizer Inc., Array BioPharma, Vericel Corporation,PhaseBio Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc, Johnson and Johnson, Merck & Co., Inc, Teva Pharmaceuticals, Astrazeneca plc and Sanofi

About Us –

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dilated Cardiomyopathy Market Size, Analysis, and Forecast Report 2017-2027 here

News-ID: 931382 • Views:

More Releases from Future Market Insights

External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Driven by Innovation and Expanding Healthcare Access
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Driven by Innovation and Expanding Healthcare Access
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Driven by Innovation and Expanding Healthcare Access
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Driven by Innovation and Expanding Healthcare Access
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,

All 5 Releases


More Releases for Dilated

Dilated Cardiomyopathy Market Forecast: Trends and Analysis 2024-2031
The "Dilated Cardiomyopathy Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside
Dilated Cardiomyopathy Market - Rebuilding Hope, Restoring Hearts: Dilated Cardi …
Newark, New Castle, USA: The "Dilated Cardiomyopathy Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Dilated Cardiomyopathy Market: https://www.growthplusreports.com/report/dilated-cardiomyopathy-market/7764 This latest report researches the industry structure, sales, revenue,
Dilated Cardiomyopathy Market Report, History and Forecast 2022-2030
Dilated Cardiomyopathy Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Dilated Cardiomyopathy industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview
Global Dilated Cardiomyopathy Market Insights, Forecast
Dilated Cardiomyopathy (DCM) refers to the cardiac hypertrophy, cannot effectively pump blood. Dilated Cardiomyopathy (DCM) is due to genetic or other disease caused by a heart disease, it respectively affect the ventricles of the heart and heart, the inferior vena chamber and the upper Chambers of the heart. The global Dilated Cardiomyopathy market is valued at 180 million US$ in 2018 and will reach 290 million US$ by the end
Dilated Cardiomyopathy Market Opportunity Analysis, 2026 – 2026
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles
Dilated Cardiomyopathy Therapeutics Market Research Report Forecast
A new market research report has been recently published by Transparency market research, a leading market intelligence firm. The research report, titled “Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, presents a market overview, market drivers, opportunities, challenges, product segmentation, and competitive landscape. The research report also features inputs and recommendations from industry experts and professionals to help the